Literature DB >> 26447063

Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.

Riley Bove1, Brian C Healy2, Alexander Musallam3, Bonnie I Glanz4, Philip L De Jager1, Tanuja Chitnis5.   

Abstract

BACKGROUND: Onset of multiple sclerosis (MS) is typically in early adulthood. The impact, if any, of menopause on the MS course is unknown. Our objective was to determine whether menopause is associated with changes in MS severity in a longitudinal clinical cohort.
METHODS: Responses from an ongoing reproductive questionnaire deployed in all active female CLIMB observational study participants with a diagnosis of clinically isolated syndrome (CIS) or MS were analyzed when the response rate was 60%. Reproductive data were linked with clinical severity measures that were prospectively collected every six months, including our primary measure, the Expanded Disability Status Scale (EDSS).
RESULTS: Over one-half of the respondents (368 of 724 women) were postmenopausal. Median age at natural menopause was 51.5 years. In our primary analysis of 124 women who were followed longitudinally (mean duration 10.4 years) through their menopausal transition (natural or surgical), menopause represented an inflection point in their EDSS changes (difference of 0.076 units; 95% CI 0.010-0.14; p = 0.024). These findings were not explained by vitamin D levels, nor changes in treatment or smoking status over this period. There was no effect of hormone replacement therapy (HRT) exposure, but HRT use was low.
CONCLUSIONS: We observed a possible worsening of MS disability after menopause. Larger cohorts are required to assess any HRT effects.
© The Author(s), 2015.

Entities:  

Keywords:  Clinically isolated syndrome; disability; disease progression; estrogen; hormone replacement therapy; menopause; multiple sclerosis; oophorectomy; patient reported outcome; quality of life

Mesh:

Year:  2015        PMID: 26447063      PMCID: PMC4824677          DOI: 10.1177/1352458515606211

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  32 in total

Review 1.  Is there a connection between estrogen and Parkinson's disease?

Authors:  Lisa M Shulman
Journal:  Parkinsonism Relat Disord       Date:  2002-06       Impact factor: 4.891

2.  Symptoms of multiple sclerosis in women in relation to sex steroid exposure.

Authors:  Per Holmqvist; Malin Wallberg; Mats Hammar; A-M Landtblom; Jan Brynhildsen
Journal:  Maturitas       Date:  2005-11-15       Impact factor: 4.342

Review 3.  The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis.

Authors:  Riley Bove; Tanuja Chitnis
Journal:  Mult Scler       Date:  2014-02-21       Impact factor: 6.312

4.  Patients report worse MS symptoms after menopause: findings from an online cohort.

Authors:  R Bove; B C Healy; E Secor; T Vaughan; B Katic; T Chitnis; P Wicks; P L De Jager
Journal:  Mult Scler Relat Disord       Date:  2014-12-09       Impact factor: 4.339

Review 5.  Vitamin D: evidence for its role as a prognostic factor in multiple sclerosis.

Authors:  Ellen M Mowry
Journal:  J Neurol Sci       Date:  2011-07-16       Impact factor: 3.181

Review 6.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 7.  Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity.

Authors:  Walter A Rocca; Brandon R Grossardt; Lynne T Shuster
Journal:  Brain Res       Date:  2010-10-18       Impact factor: 3.252

Review 8.  EMAS position statement: managing the menopause in women with epilepsy.

Authors:  C Tamer Erel; Marc Brincat; Marco Gambacciani; Irene Lambrinoudaki; Mette H Moen; Karin Schenck-Gustafsson; Florence Tremollieres; Svetlana Vujovic; Serge Rozenberg; Margaret Rees
Journal:  Maturitas       Date:  2010-04-24       Impact factor: 4.342

9.  Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study.

Authors:  Huibo Shao; John C S Breitner; Rachel A Whitmer; Junmin Wang; Kathleen Hayden; Heidi Wengreen; Chris Corcoran; Joann Tschanz; Maria Norton; Ron Munger; Kathleen Welsh-Bohmer; Peter P Zandi
Journal:  Neurology       Date:  2012-10-24       Impact factor: 9.910

10.  Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis.

Authors:  Brian C Healy; David Engler; Bonnie Glanz; Alexander Musallam; Tanuja Chitnis
Journal:  Mult Scler Int       Date:  2013-03-10
View more
  16 in total

1.  Ovarian aging is associated with gray matter volume and disability in women with MS.

Authors:  Jennifer S Graves; Roland G Henry; Bruce A C Cree; Geralyn Lambert-Messerlian; Ruth M Greenblatt; Emmanuelle Waubant; Marcelle I Cedars; Alyssa Zhu; Peter Bacchetti; Stephen L Hauser; Jorge R Oksenberg
Journal:  Neurology       Date:  2017-12-22       Impact factor: 9.910

Review 2.  Remyelinating Pharmacotherapies in Multiple Sclerosis.

Authors:  Riley M Bove; Ari J Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  PLXNA3 Variant rs5945430 is Associated with Severe Clinical Course in Male Multiple Sclerosis Patients.

Authors:  Moaz Qureshi; Mohamed Hatem; Raed Alroughani; Sindhu P Jacob; Rabeah Abbas Al-Temaimi
Journal:  Neuromolecular Med       Date:  2017-05-23       Impact factor: 3.843

Review 4.  Caring for Women with Multiple Sclerosis Across the Lifespan.

Authors:  Kelsey Rankin; Riley Bove
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 5.  Optic neuritis secondary to antiandrogen therapy.

Authors:  Á Ní Mhéalóid; G Cunniffe
Journal:  Ir J Med Sci       Date:  2016-12-30       Impact factor: 1.568

Review 6.  The effect of sex on multiple sclerosis risk and disease progression.

Authors:  Rhonda R Voskuhl
Journal:  Mult Scler       Date:  2020-01-22       Impact factor: 6.312

Review 7.  Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review.

Authors:  Riley Bove; Annette Okai; Maria Houtchens; Birte Elias-Hamp; Alessandra Lugaresi; Kerstin Hellwig; Eva Kubala Havrdová
Journal:  Front Neurol       Date:  2021-03-19       Impact factor: 4.003

Review 8.  Lost in translational biology: Understanding sex differences to inform studies of diseases of the nervous system.

Authors:  Richard V Pearse; Tracy L Young-Pearse
Journal:  Brain Res       Date:  2019-07-25       Impact factor: 3.610

9.  Quantitative effect of sex on disease activity and disability accumulation in multiple sclerosis.

Authors:  Melinda Magyari; Nils Koch-Henriksen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-04-07       Impact factor: 13.654

10.  Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.

Authors:  Riley Bove; Charles C White; Kathryn C Fitzgerald; Tanuja Chitnis; Lori Chibnik; Alberto Ascherio; Kassandra L Munger
Journal:  Neurology       Date:  2016-09-07       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.